Anbio Biotechnology [NNNN] vs Becton, Dickinson [BDX] Detailed Stock Comparison
Anbio Biotechnology
NASDAQ
Loading...
Becton, Dickinson
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Anbio Biotechnology wins in 5 metrics, Becton, Dickinson wins in 10 metrics, with 0 ties. Becton, Dickinson appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Anbio Biotechnology | Becton, Dickinson | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 643.20 | 35.46 | Becton, Dickinson |
| Price-to-Book Ratio | 79.02 | 2.18 | Becton, Dickinson |
| Debt-to-Equity Ratio | 0.00 | 75.93 | Anbio Biotechnology |
| PEG Ratio | N/A | 1.86 | N/A |
| EV/EBITDA | 595.05 | 12.52 | Becton, Dickinson |
| Profit Margin (TTM) | 28.99% | 7.41% | Anbio Biotechnology |
| Operating Margin (TTM) | -68.64% | 17.81% | Becton, Dickinson |
| EBITDA Margin (TTM) | N/A | 17.81% | N/A |
| Return on Equity | 14.83% | 6.18% | Anbio Biotechnology |
| Return on Assets (TTM) | 7.18% | 3.96% | Anbio Biotechnology |
| Free Cash Flow (TTM) | $2.08M | $3.07B | Becton, Dickinson |
| Dividend Yield | N/A | 1.80% | N/A |
| 1-Year Return | 457.37% | -18.73% | Anbio Biotechnology |
| Price-to-Sales Ratio (TTM) | 172.45 | 2.59 | Becton, Dickinson |
| Enterprise Value | $1.40B | $74.08B | Becton, Dickinson |
| EV/Revenue Ratio | 171.02 | 3.46 | Becton, Dickinson |
| Gross Profit Margin (TTM) | N/A | 47.81% | N/A |
| Revenue per Share (TTM) | $0 | $74 | Becton, Dickinson |
| Earnings per Share (Diluted) | $0.05 | $5.46 | Becton, Dickinson |
| Beta (Stock Volatility) | N/A | 0.28 | N/A |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Anbio Biotechnology vs Becton, Dickinson Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Anbio Biotechnology | -3.42% | -7.96% | -31.98% | -13.06% | 342.37% | 457.37% |
| Becton, Dickinson | -0.84% | 4.88% | 2.11% | 9.91% | -12.63% | -14.52% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Anbio Biotechnology | 457.37% | 457.37% | 457.37% | 457.37% | 457.37% | 457.37% |
| Becton, Dickinson | -18.73% | -13.05% | -16.37% | 44.06% | 165.47% | 282.86% |
News Based Sentiment: Anbio Biotechnology vs Becton, Dickinson
Anbio Biotechnology
News based Sentiment: MIXED
October was a highly volatile month for Anbio Biotechnology, with significant price swings and conflicting signals. The company demonstrated strong financial health, but bearish technical indicators and concerns about financial manipulation create a mixed investment picture. The dramatic intraday reversals highlight the stock's sensitivity to market sentiment.
Becton, Dickinson
News based Sentiment: POSITIVE
Becton Dickinson had a strong month driven by a significant earnings beat, upward guidance revision, and a strategic partnership focused on the growing pharmacy automation market. While insider selling exists, the overall narrative is positive, supported by high institutional ownership and positive analyst coverage.
Performance & Financial Health Analysis: Anbio Biotechnology vs Becton, Dickinson
| Metric | NNNN | BDX |
|---|---|---|
| Market Information | ||
| Market Cap | $1.41B | $55.67B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 103,020 | 1,421,540 |
| 90 Day Avg. Volume | 65,163 | 1,589,433 |
| Last Close | $31.06 | $191.99 |
| 52 Week Range | $5.18 - $55.65 | $163.33 - $251.99 |
| % from 52W High | -44.19% | -23.81% |
| All-Time High | $55.65 (Jul 15, 2025) | $287.32 (Jul 24, 2023) |
| % from All-Time High | -44.19% | -33.18% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.36% | 0.10% |
| Quarterly Earnings Growth | N/A | 0.18% |
| Financial Health | ||
| Profit Margin (TTM) | 0.29% | 0.07% |
| Operating Margin (TTM) | -0.69% | 0.18% |
| Return on Equity (TTM) | 0.15% | 0.06% |
| Debt to Equity (MRQ) | 0.00 | 75.93 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $0.41 | $88.87 |
| Cash per Share (MRQ) | $0.27 | $2.64 |
| Operating Cash Flow (TTM) | $2.08M | $3.25B |
| Levered Free Cash Flow (TTM) | $1.27M | $3.37B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.80% |
| Last 12-Month Dividend | N/A | $3.03 |
Valuation & Enterprise Metrics Analysis: Anbio Biotechnology vs Becton, Dickinson
| Metric | NNNN | BDX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 643.20 | 35.46 |
| Forward P/E | N/A | 12.31 |
| PEG Ratio | N/A | 1.86 |
| Price to Sales (TTM) | 172.45 | 2.59 |
| Price to Book (MRQ) | 79.02 | 2.18 |
| Market Capitalization | ||
| Market Capitalization | $1.41B | $55.67B |
| Enterprise Value | $1.40B | $74.08B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 171.02 | 3.46 |
| Enterprise to EBITDA | 595.05 | 12.52 |
| Risk & Other Metrics | ||
| Beta | N/A | 0.28 |
| Book Value per Share (MRQ) | $0.41 | $88.87 |
Financial Statements Comparison: Anbio Biotechnology vs Becton, Dickinson
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | NNNN | BDX |
|---|---|---|
| Revenue/Sales | N/A | $5.51B |
| Cost of Goods Sold | N/A | $2.88B |
| Gross Profit | N/A | $2.63B |
| Research & Development | N/A | $297.00M |
| Operating Income (EBIT) | N/A | $979.00M |
| EBITDA | N/A | $1.57B |
| Pre-Tax Income | N/A | $703.00M |
| Income Tax | N/A | $129.00M |
| Net Income (Profit) | N/A | $574.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | NNNN | BDX |
|---|---|---|
| Cash & Equivalents | $11.76M | $667.00M |
| Total Current Assets | $18.53M | $8.67B |
| Total Current Liabilities | $1.73M | $7.69B |
| Long-Term Debt | N/A | $17.67B |
| Total Shareholders Equity | $17.19M | $25.24B |
| Retained Earnings | $17.17M | $16.15B |
| Property, Plant & Equipment | N/A | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | NNNN | BDX |
|---|---|---|
| Operating Cash Flow | N/A | $941.00M |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | $35.00M |
| Debt Repayment | N/A | $-1.00M |
| Common Stock Repurchase | N/A | $0 |
Short Interest & Institutional Ownership Analysis
| Metric | NNNN | BDX |
|---|---|---|
| Shares Short | 163,788 | 4.28M |
| Short Ratio | 2.73 | 2.41 |
| Short % of Float | 0.00% | 0.02% |
| Average Daily Volume (10 Day) | 103,020 | 1,421,540 |
| Average Daily Volume (90 Day) | 65,163 | 1,589,433 |
| Shares Outstanding | 43.89M | 289.10M |
| Float Shares | 39.69M | 286.00M |
| % Held by Insiders | 0.05% | 0.01% |
| % Held by Institutions | 0.05% | 0.92% |
Dividend Analysis & Yield Comparison: Anbio Biotechnology vs Becton, Dickinson
| Metric | NNNN | BDX |
|---|---|---|
| Last 12-Month Dividend | N/A | $3.03 |
| Last 12-Month Dividend Yield | N/A | 1.80% |
| 3-Year Avg Annual Dividend | N/A | $3.16 |
| 3-Year Avg Dividend Yield | N/A | 0.40% |
| 3-Year Total Dividends | N/A | $9.48 |
| Ex-Dividend Date | N/A | Mar 10, 2025 |